Sanofi concludes Blueprint Medicines acquisition

finance.yahoo.com/news/sanofi-concludes-blueprint-medicines-acquisition-113116432.html

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the expertise of a company focused on systemic mastocytosis (SM) and other KIT-driven diseases.
In June 2025, Sanofi agreed to acquire Blueprint for an equity value of…

This story appeared on finance.yahoo.com, 2025-07-21 11:31:16.
The Entire Business World on a Single Page. Free to Use →